Prognostic significance of serum lactate dehydrogenase in patients undergoing radical cystectomy for bladder cancer

Su, Shiqiang; Liu, Li-Zhe; Sun, Chao; Yang, Lijun; Nie, Yanhua; Chen, Yan; Zhang, Jin; Shen, Li

doi:10.1016/j.urolonc.2020.05.031

Cited by 7 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since cancer cells prioritize glycolysis and lactate dehydrogenase catalyzes pyruvate and lactic acid, the enzyme’s serum level might reflect the metabolic changes seen in tumor progression. An elevated lactate dehydrogenase level was associated with a shorter disease-free survival (HR 2.051; p = 0.019) [ 41 ]. With its feasibility and easy access, the measurement of serum lactate dehydrogenase might therefore be a promising part of a risk stratification panel.…”

Section: Resultsmentioning

confidence: 99%

Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis

Ofner

Laukhtina

Hassler

et al. 2023

IJMS

View full text Add to dashboard Cite

Survival outcomes after radical cystectomy (RC) for bladder cancer (BCa) have not improved in recent decades; nevertheless, RC remains the standard treatment for patients with localized muscle-invasive BCa. Identification of the patients most likely to benefit from RC only versus a combination with systemic therapy versus systemic therapy first/only and bladder-sparing is needed. This systematic review and meta-analysis pools the data from published studies on blood-based biomarkers to help prognosticate disease recurrence after RC. A literature search on PubMed and Scopus was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. Articles published before November 2022 were screened for eligibility. A meta-analysis was performed on studies investigating the association of the neutrophil-to-lymphocyte ratio (NLR), the only biomarker with sufficient data, with recurrence-free survival. The systematic review identified 33 studies, and 7 articles were included in the meta-analysis. Our results demonstrated a statistically significant correlation between elevated NLR and an increased risk of disease recurrence (HR 1.26; 95% CI 1.09, 1.45; p = 0.002) after RC. The systematic review identified various other inflammatory biomarkers, such as interleukin-6 or the albumin-to-globulin ratio, which have been reported to have a prognostic impact on recurrence after RC. Besides that, the nutritional status, factors of angiogenesis and circulating tumor cells, and DNA seem to be promising tools for the prognostication of recurrence after RC. Due to the high heterogeneity between the studies and the different cut-off values of biomarkers, prospective and validation trials with larger sample sizes and standardized cut-off values should be conducted to strengthen the approach in using biomarkers as a tool for risk stratification in clinical decision-making for patients with localized muscle-invasive BCa.

show abstract

Section: Resultsmentioning

confidence: 99%

Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis

Ofner

Laukhtina

Hassler

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Subsequently, a prognostic score for OS was proposed in ipilimumab-treated patients with advanced melanoma, which included LDH, ECOG PS and number of organs involved [ 23 ]. LDH level may be an important prognostic factor for survival in bladder cancer [ 24 ] but it is typically not reported in clinical studies of ICIs in advanced disease. Based on the results of our univariable analysis and the model of Sonpavde et al [ 18 ], baseline LDH levels may also have prognostic value for survival outcomes in platinum-treated mUC.…”

Section: Discussionmentioning

confidence: 99%

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma

Alt,

Stecca,

Lin

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background This retrospective analysis of data from clinical trials in metastatic urothelial carcinoma (mUC) was conducted to determine baseline patient characteristics associated with long-term survival (LTS) following treatment with immune checkpoint inhibitors. Methods Data for this analysis were from patients with platinum-refractory mUC who received durvalumab or durvalumab plus tremelimumab in phase 1/2 studies. The primary outcome measure was LTS. Patients were categorised as overall survival (OS) ≥ 2 years (from first dose) or OS < 2 years. A univariable analysis assessed independent associations with LTS and multivariable logistic regression was employed including each variable with P ≤ 0.05 as covariates. Results Among 360 patients, 88 (24.4%) had OS ≥ 2 years and 272 (75.6%) had OS < 2 years. In univariable analysis, several baseline characteristics and laboratory measurements were associated with LTS including sex, ECOG PS, PD-L1 expression, prior surgery, time from initial diagnosis, lymph node-only involvement, visceral disease, haemoglobin level, absolute neutrophil count, neutrophil–lymphocyte ratio and lactate dehydrogenase level. In multivariable analysis, LTS was significantly associated with ECOG PS, PD-L1 expression, haemoglobin level and absolute neutrophil count. Conclusions Several baseline clinical characteristics and laboratory measurements were associated with LTS for patients with platinum-refractory mUC treated with durvalumab or durvalumab plus tremelimumab.

show abstract

“…Postoperative variables consisted of surgical and pathological variables, including surgical approach and procedure, pT stage, status of lymph node, surgical margin, postoperative chemotherapy. The cut-off values of hemoglobin, white blood cell, PLR, NLR, LMR, albumin were decided according to our previous study (4). The best cut-off point of preoperative GGT was estimated through receiver operating characteristic (ROC) curve analysis, which was used as a classification variable to divide the whole cohort into two groups.…”

Section: Variablesmentioning

confidence: 99%

Preoperative Serum Gamma-Glutamyltransferase as a Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer

Liu

Sun

et al. 2021

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

BackgroundSerum gamma-glutamyltransferase (GGT) has been reported to be correlated with survival in a variety of malignancies. However, its effect on patients with bladder cancer (BC) treated by radical cystectomy has never been evaluated.Patients and MethodsWe retrospectively evaluated 263 patients who underwent radical surgery in our center. Baseline features, hematologic variables, and follow-up data were obtained. The endpoints included overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). The relationship between GGT and survival were evaluated.ResultsThe median follow-up period for all patients was 34.7 (22.9-45.9) months. At the last follow-up, 67 patients died, 51 patients died of cancer, 92 patients experienced disease recurrence. Patients with an elevated serum GGT had a higher rate of pT3-T4 tumors. Patients with a higher preoperative serum GGT had a lower rate of OS, CSS and DFS (P < 0.001 for all). Multivariate analysis identified that preoperative serum GGT was independent predictor of OS (HR: 3.027, 95% CI: 1.716-5.338; P < 0.001), CSS (HR: 2.115, 95% CI: 1.093-4.090; P = 0.026), DFS (HR: 2.584, 95% CI: 1.569-4.255; P < 0.001). Age, diabetes history, pathologic T stage, and lymph node status also were independent predictors of prognosis for BC patients.ConclusionsOur results indicated that preoperative serum GGT was an independent prognosis predictor for survival of BC patients after radical cystectomy, and can be included in the prognostic models.

show abstract

Prognostic significance of serum lactate dehydrogenase in patients undergoing radical cystectomy for bladder cancer

Cited by 7 publications

References 24 publications

Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis

Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma

Preoperative Serum Gamma-Glutamyltransferase as a Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer

Contact Info

Product

Resources

About